Zydus Lifesciences Ltd - 532321 - Board Meeting Intimation for Approval Of Unaudited Financial Results
Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2023 ,inter alia, to consider and approve unaudited financial results for the quarter / nine months ended on December 31, 2022. Zydus Lifesciences Ltd - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate under regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives tentative approval from the USFDA for Levomilnacipran Extended-Release Capsules Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval and 180 days shared exclusivity from the USFDA for Brexpiprazole Tablets Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Credit Rating
Credit Ratings Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Febuxostat Tablets Zydus Lifesciences Ltd - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate under regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus launches Topiramate Extended-Release Capsules Zydus Lifesciences Ltd - 532321 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliance Certificate under Reg 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended on December 31, 2022 Zydus Lifesciences Ltd - 532321 - Transcript Of The 1St Extra Ordinary General Meeting Of The Financial Year 2022-2023 Of The Members Of The Company
Transcript of the 1st Extra Ordinary General Meeting of the Financial Year 2022-2023 of the members of the Company